Physician profile
Danielle Bogue
NPI 1295062537
$9,460.87
in general payments reported to CMS, 2019-2025
30 companies · $2,117 in 2025
The $2,117 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,763 · 2022: $1,898 · 2023: $2,262 · 2024: $1,421 · 2025: $2,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,793 · Education: $6.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,792.69 |
| Education | $6.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,730.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,795.18 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,474.43 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $687.48 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $468.45 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $277.87 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.69 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $239.76 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $171.13 | 2021 | |
| Janssen Pharmaceuticals, INC | $162.76 | 2022-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $143.46 | 2023 | Quviviq |
| Abbott Laboratories | $143.29 | 2022-2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $124.94 | 2025 | Auvelity |
| Alexion Pharmaceuticals, INC. | $119.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $103.53 | 2024 | Austedo Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.86 | 2021-2022 | |
| Amgen INC. | $78.66 | 2023-2025 | Repatha, Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $65.21 | 2022-2023 | Seglentis, Livalo |
| Impel Pharmaceuticals INC. | $56.33 | 2022-2023 | Trudhesa |
| Merck Sharp & Dohme LLC | $43.86 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.41 | 2023 | |
| Seqirus USA INC | $30.08 | 2025 | Fluad, Flucelvax |
| Sumitomo Pharma America, INC. | $20.90 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $16.82 | 2022 | |
| Astellas Pharma US INC | $16.71 | 2023 | Veozah |
| Eisai INC. | $16.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.53 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.32 | 2023 | Linzess |
| Amarin Pharma, INC. | $15.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Bogue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.